Myeg returned for augmented reality technology developer HiScene's $41.6m series C-plus round while celiac disease drug developer Calypso Biotech hiked a corporate-backed round to over $33m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Based on technology at University of Pennsylvania, iEcure has launched to commercialise gene therapies initially for liver disorders and an option to license more assets.

Allianz has recommitted to the venture capital firm having funded its $170m debut vehicle two years ago.

Disease diagnostics technology developer Mammoth Biosciences is valued at over $1bn following funding rounds backed by investors including Amazon.

Sanofi and Alexandria Real Estate Equities could exit the chronic disease therapeutics developer, which has set the range for an offering that could raise up to $170m.

Illumina’s corporate venturing unit took part in a round that brought the proteomic platform developer’s overall funding to $110m.

Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.

Q&A with William Taranto, president, Merck Global Health Innovation (GHI) Fund, and vice-president, Merck Global Health Innovation Group

Parkwalk Advisors and Cambridge Innovation Capital have backed the pet antibody therapeutics developer, a spinout of Wellcome Sanger Institute.